Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted): 2023-2024

Historic EPS (Weighted Average and Diluted) for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to -$1.41.

  • CG Oncology's EPS (Weighted Average and Diluted) fell 90.00% to -$0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.04, marking a year-over-year increase of 62.29%. This contributed to the annual value of -$1.41 for FY2024, which is 90.99% up from last year.
  • Latest data reveals that CG Oncology reported EPS (Weighted Average and Diluted) of -$1.41 as of FY2024, which was up 90.99% from -$15.65 recorded in FY2023.
  • In the past 5 years, CG Oncology's EPS (Weighted Average and Diluted) registered a high of -$1.41 during FY2024, and its lowest value of -$15.65 during FY2023.
  • Moreover, its 2-year median value for EPS (Weighted Average and Diluted) was -$8.53 (2024), whereas its average is -$8.53.
  • Data for CG Oncology's EPS (Weighted Average and Diluted) shows a peak YoY surged of 90.99% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's EPS (Weighted Average and Diluted) (Yearly) stood at -$15.65 in 2023, then surged by 90.99% to -$1.41 in 2024.